Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 18.8 Cr.
- Current Price ₹ 43.7
- High / Low ₹ 61.0 / 29.6
- Stock P/E 10.6
- Book Value ₹ 38.8
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.20 times its book value
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 33.41 | |
| 30.38 | |
| Operating Profit | 3.03 |
| OPM % | 9.07% |
| 0.00 | |
| Interest | 0.31 |
| Depreciation | 0.10 |
| Profit before tax | 2.62 |
| Tax % | 23.28% |
| 2.02 | |
| EPS in Rs | 4.68 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 2.92 | |
| -1.15 | |
| -0.33 | |
| Net Cash Flow | 1.45 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Trade Receivable Turnover Ratio Times ・Standalone data |
|
||
| Medical Representatives (MR) Reimbursement Expense INR Lakhs ・Standalone data |
|||
| Number of Employees Number ・Standalone data |
|||
| Number of Subsidiaries Number ・Standalone data |
|||
Documents
Announcements
-
Outcome of Board Meeting
13 February 2026 - Board approved rights issue to raise up to Rs15.10 crore; DLOF approved; NSE approval pending.
-
Trading Window
10 February 2026 - Trading window closed Feb 10 until 48 hours after Feb 13 board meeting for proposed equity/preferential fundraise.
-
Resignation
16 January 2026 - Resignation of CS Neelam Gattani effective 13 Jan 2026; Nabil Ansari appointed CS & Compliance Officer effective 16 Jan 2026.
-
Change in Company Secretary/Compliance Officer
16 January 2026 - CS Neelam Gattani resigned effective 13 Jan 2026; CS Nabil Ansari appointed effective 16 Jan 2026.
-
Appointment
16 January 2026 - Resignation of CS Neelam Gattani effective 13 Jan 2026; Nabil Ansari appointed CS effective 16 Jan 2026.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste